Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

HR+/HER2- Early Breast Cancer 1HR+/HER2+ Early Breast Cancer 1Breast Neoplasms 1

Interventions

Specimen Handling 136Magnetic Resonance Spectroscopy 110Biopsy 82pembrolizumab 64Nivolumab 59Carboplatin 59Cyclophosphamide 55Cisplatin 53Paclitaxel 46Gemcitabine 39Bevacizumab 39Radiotherapy 36Dexamethasone 34Doxorubicin 28atezolizumab 27Rituximab 27olaparib 25durvalumab 25venetoclax 24Pemetrexed 24Fluorouracil 24Cytarabine 24fludarabine 22Vincristine 22Prednisone 22Lenalidomide 22Injections 22Immunoglobulin G 22130-nm albumin-bound paclitaxel 22X-Rays 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Aromatase Inhibitors × 30 days × Clear all
NCT07618923 2026-06-11

TD-DASHER-01

Tang-Du Hospital

Phase 2 Not yet recruiting
20 enrolled
Breast

Breast Neoplasms

NCT07616427 2026-06-01

TAYLOR-003

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
100 enrolled
Breast

HR+/HER2+ Early Breast Cancer

NCT07616453 2026-06-01

TAYLOR-002

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
45 enrolled
Breast

HR+/HER2- Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡